Also trades as: GUD.TO (TSX) · $vol 1M
KHTRF OTC
Knight Therapeutics Inc.
1W: +4.0%
1M: +8.1%
3M: +8.1%
YTD: +71.7%
1Y: +69.0%
3Y: +106.3%
5Y: +73.7%
$7.47
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$450M
+21.1% ▲
5Y CAGR: +17.6%
Gross Profit
$151M
-13.6% ▼
5Y CAGR: +13.0%
Operating Income
-$2M
-129.7% ▼
Net Income
-$5M
-224.0% ▼
EPS (Diluted)
$-0.05
-225.9% ▼
EBITDA
$54M
-15.6% ▼
5Y CAGR: +13.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $243M | $294M | $328M | $371M | $450M |
| YoY Growth | +22.0% | +20.6% | +11.8% | +13.1% | +21.1% |
| Cost of Revenue | $128M | $156M | $176M | $197M | $299M |
| Gross Profit | $115M | $138M | $153M | $174M | $151M |
| Gross Margin | 47.4% | 47.0% | 46.5% | 47.0% | 33.5% |
| R&D Expenses | $13M | $15M | $18M | $23M | $29M |
| SG&A Expenses | $74M | $89M | $84M | $99M | $124M |
| Operating Expenses | $128M | $155M | $156M | $167M | $153M |
| Operating Income | -$5M | -$2M | -$3M | $7M | -$2M |
| Operating Margin | -2.2% | -0.8% | -0.9% | 2.0% | -0.5% |
| Interest Expense | $4M | $7M | $12M | $9M | $10M |
| Income Before Tax | $7M | -$44M | -$22M | $2M | -$7M |
| Tax Expense | -$9M | -$14M | -$5M | -$2M | -$1M |
| Net Income | $16M | -$30M | -$17M | $4M | -$5M |
| Net Margin | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| EPS (Diluted) | $0.13 | $-0.26 | $-0.16 | $0.04 | $-0.05 |
| EBITDA | $43M | $25M | $41M | $64M | $54M |
| Shares Outstanding | 125M | 115M | 107M | 101M | 100M |